Semax Dosage: Evidence, Label Context and Safety (2026)
Semax has been studied in small healthy-volunteer experiments and neurological patient populations, with different formulations and exposures. Some reports show promising findings, but they do not establish one dose for every cognitive goal. This guide compares those studies with a specific Russian nasal-drop label, explains concentration math and separates what is known from online protocol claims. For background, see the Semax peptide overview.
Semax Dosage Chart: Evidence, Not a Universal Protocol
The table separates manufacturer directions from original human research. Study exposures describe what researchers tested, not a recommended starting dose or self-treatment schedule.
| Source context | Population or product | Route | Exposure or label context | Endpoint or relevance | Limits |
|---|---|---|---|---|---|
| Peptogen 0.1% label | A manufacturer-hosted Russian 0.1% nasal-drop product label | Intranasal drops | 50 mcg per product drop; 400–900 mcg/day for 3–5 days in the first half of the day for a mental-fatigue context | Manufacturer directions for that liquid product | Manufacturer-hosted label, not a generic US recommendation or a spray/injection instruction |
| Gusev et al. 2018 (PMID 29798983) | 110 adults after ischemic stroke; early and late rehabilitation groups | 1% nasal drops in the study report | 6,000 mcg/day in two 10-day courses with a 20-day interval | Authors reported higher plasma BDNF and improved Barthel functional recovery; motor/paresis recovery also depended on rehabilitation timing | Disease-specific rehabilitation context; no placebo or blinding description; not a nootropic cycle or general dose |
| Kaplan et al. 1996 human pilot | 16 healthy male operators; 8/8 randomized, double-blind groups | Intranasal | 1 mg on two workdays | Task-performance benefit was reported, but spontaneous (false) responses also increased | Small, short pilot; not a general regimen or long-term efficacy and safety study |
| Panikratova et al. 2020 | 52 healthy participants across separate Semax, Selank and placebo groups | Intranasal Semax in the study | One exposure; brain imaging before and 5/20 minutes afterward | Reported differences in resting-state functional connectivity | Imaging endpoint, not demonstrated memory improvement or a combined Semax/Selank stack |
What a “Standard Dose” Claim Can and Cannot Mean
The sources above use different populations, products and outcomes. A small task-performance experiment and a post-stroke rehabilitation study cannot be combined into a universal “standard nootropic dose.” The useful question is which exact product and intended outcome a dose claim comes from.
The manufacturer-hosted 0.1% nasal-drop instruction is narrower: it identifies a particular liquid product, 50 mcg per drop and a 400–900 mcg/day, 3–5-day first-half-of-day context for mental fatigue. That context should not be presented as a universal US dose, a dose for every formulation or evidence of benefit for healthy users.
A small 1996 human pilot adds limited positive cognitive evidence: 16 healthy male operators were split 8/8 in a randomized, double-blind design and received 1 mg intranasally on two workdays. The report described task-performance benefits, but spontaneous (false) responses also increased. Its size and short exposure do not establish a general regimen, predictable onset or long-term safety; read the Kaplan et al. report in that context.
Intranasal Product Context and Reconstitution Math
The Peptogen document describes 0.1% nasal drops containing 1 mg/mL Semax, methylparaben and purified water. Its 50 mcg amount belongs to that product’s dropper. It is not a recipe for diluting a powder vial into a fine-mist sprayer.
Arithmetic is a separate question from pharmaceutical suitability. If a final solution actually contained 10 mg in 2 mL, its concentration would be 5 mg/mL. A hypothetical 0.1 mL volume at that concentration contains 0.5 mg, or 500 mcg. That example does not verify a device output, sterility, stability, absorption or a patient dose. Do not transfer nasal-drop amounts to an injection. Product-specific storage and discard instructions control; our peptide storage guide cannot replace a label or pharmacy direction.
Subcutaneous Semax: Evidence Gap, Not a Dose
The May 2026 FDA briefing found no human subcutaneous safety data and no identified human pharmacokinetic studies. It distinguishes free base from acetate and highlights formulation and device controls. This advisory briefing is not final agency action. The online 200–400 mcg injection range is not a validated human dose in the reviewed studies. A delivery advantage over nasal use has not been established.
The general technique in how to inject BPC-157 is not a Semax prescribing or sterility guide. A clinician and dispensing pharmacy would need to identify the exact active form, route, concentration, formulation, device and instructions. Nasal-label math cannot establish subcutaneous absorption, timing or safety.
Timing and Onset
The reviewed sources do not establish a universal onset window, predictable absorption curve or morning schedule for every Semax product. The 0.1% label places its mental-fatigue context in the first half of the day, but that product instruction is not proof that all formulations produce a particular alertness effect or that a second dose belongs before a fixed hour.
In the 2020 imaging study, scans at 5 and 20 minutes measured brain connectivity, not when participants felt more focused. Kaplan’s operator experiment assessed performance after administration and into the next day. Neither design establishes a general 15–30-minute subjective onset or a repeat-dose rule. Anecdotal reports of alertness can be described as experiences, not a predictable response for everyone.
Cycling and Repeat Courses
The original post-stroke report studied 110 adults in early or late rehabilitation. Authors reported random subgrouping, higher BDNF and improved Barthel functional recovery; motor/paresis recovery was also tied to rehabilitation timing, and the report does not describe placebo control or blinding. Its 1% nasal-drop exposure was two 10-day courses separated by 20 days, alongside rehabilitation. That is useful human disease-context evidence, but it is not a healthy-person cognitive cycle or proof that the interval prevents tolerance.
No reviewed human source establishes a tolerance-reset mechanism, a required break or a safe long-term repeat schedule. A repeat course should therefore remain a product- and indication-specific clinical decision, not an online protocol.
Stacking with Selank
The 2020 study compared separate Semax, Selank and placebo groups; participants were not testing a Semax-plus-Selank stack. There is no controlled human evidence in the sources reviewed here that combining them produces a balancing effect or a safety advantage. Reports of “stimulating” and “calming” experiences remain anecdotal rather than proof that the effects cancel or complement each other.
Keep the evidence boundary explicit when reading our Selank guide and Semax vs Selank comparison: discussion of two separate peptides is not evidence that a stack is effective, balanced or safe for a particular person.
Side Effects and Safety
The manufacturer-hosted label reports possible mild nasal irritation with prolonged use and lists pregnancy, lactation, acute mental states, disorders accompanied by anxiety and a history of seizures among its contraindications. Those statements belong to that labeled product and should not be silently transferred to an unidentified powder or compound.
The FDA review raises potential bleeding concerns and potential immunogenicity or aggregation concerns, including for injection. These are not quantified human event rates. It also notes uncertainty about the active form in clinical reports. Small, short studies and reassuring personal experiences leave long-term safety unresolved; this is an evidence limitation, not proof that every exposure is harmful. Product, route and other medicines belong in an individualized clinical discussion.
Frequently Asked Questions About Semax
This page does not establish a universal US or cognitive-enhancement dose. A manufacturer-hosted Russian 0.1% nasal-drop label gives a 400–900 mcg/day context for mental-fatigue prevention for 3–5 days in the first half of the day, but that is product-specific label information, not a general recommendation for a spray, compound or research product.
Drops and sprays are not interchangeable units. The reviewed 0.1% product label specifies 50 mcg per drop, not per spray. A spray amount requires the exact concentration and verified pump output; concentration arithmetic alone does not establish formulation suitability or a clinical dose.
No route-independent frequency is established by the sources reviewed here. The post-stroke study used two study-specific 10-day courses separated by 20 days alongside rehabilitation; that exposure should not be converted into a healthy-person schedule or a cognitive cycle.
The 0.1% label places its mental-fatigue context in the first half of the day, but the reviewed evidence does not establish a universal onset window or morning protocol for every Semax product. Use the directions for the exact labeled or prescribed product rather than assuming a predictable 15–30 minute effect.
The reviewed human studies used the nasal route and do not validate a subcutaneous regimen. A nasal label or arithmetic example cannot establish an injection dose; the linked injection guide is general technique context, not a Semax regimen.
There is no validated tolerance-reset or cycle calendar in the evidence reviewed here. The 10-day courses separated by 20 days came from a post-stroke rehabilitation study, not a healthy nootropic protocol. Do not treat that disease-study exposure as a recommendation for repeated self-use.
The sources reviewed here do not establish that Semax plus Selank produces a balancing effect, a safety advantage or a reliable combined outcome. A combination claim should remain an evidence gap, not a standard stack. See our Semax vs Selank comparison for broader context.
The manufacturer label reports possible mild nasal irritation with prolonged use and lists pregnancy, lactation and a history of seizures among its contraindications. Small, short studies cannot establish long-term safety. The safety section below distinguishes potential bleeding and immune-response concerns from measured human event rates.